Osteoporosis—the disease of the 21st century?

Clark, Stephanie

doi:10.1016/s0140-6736(02)08662-2

Cited by 11 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 9 By the year 2020 it is projected that the UK population aged over 85 years will double from 1.2 million to 2.1 million, so the prevention of fragility fractures will assume increasing importance. 10 Although for many years there was awareness of the morbidity and mortality associated with fragility fractures, real progress only came with the ability to diagnose osteoporosis before fractures occur and with the development of effective treatments. Measurements of bone mineral density (BMD) played a crucial role in both these developments.…”

mentioning

confidence: 99%

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

Blake

Fogelman

2007

Postgraduate Medical Journal

399

253

View full text Add to dashboard Cite

Dual energy x ray absorptiometry (DXA) scans to measure bone mineral density (BMD) at the spine and hip have an important role in the evaluation of individuals at risk of osteoporosis, and in helping clinicians advise patients about the appropriate use of antifracture treatment. Compared with alternative bone densitometry techniques, hip and spine DXA examinations have a number of advantages that include a consensus that BMD results can be interpreted using the World Health Organization T-score definition of osteoporosis, a proven ability to predict fracture risk, proven effectiveness at targeting antifracture therapies, and the ability to monitor response to treatment. This review discusses the evidence for these and other clinical aspects of DXA scanning, including its role in the new WHO algorithm for treating patients on the basis of their individual fracture risk.

show abstract

mentioning

confidence: 99%

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

Blake

Fogelman

2007

Postgraduate Medical Journal

399

253

View full text Add to dashboard Cite

show abstract

“…5,8,29 Similarly the age range in the sample was reflective of usual prevalence, 1 as was the prevalence of low-trauma wrist fracture. 5,7 This and the consistency of the findings of the repeat audit suggest that the findings can be generalised to other time periods within the two sample years.…”

Section: Demographicsmentioning

confidence: 93%

Evaluation of current practice: compliance with osteoporosis clinical guidelines in an outpatient fracture clinic

Kimber

Grimmer

2008

Aust. Health Review

View full text Add to dashboard Cite

Better detection and management of osteoporosis will reduce unnecessary health expenditure. A number of high quality guidelines are available to support early detection and best practice management of osteoporosis in hospital settings. However, sustainable implementation of guidelines poses practical issues in terms of structure and processes in hospitals. This paper describes an investigation into guideline compliance in one large tertiary metropolitan hospital and discusses practical elements of guideline implementation.Given the evidence of poor practice across the two audit periods, we recommend that a coordinated clinical pathway be implemented in the fracture clinic, supported by a targeted and disciplinespecific training program. Small steps towards improving awareness and management of osteoporosis in patients presenting for the first time with non-trauma wrist fracture may well produce

show abstract

“…Osteoporotic fractures are a significant cause of disability and are becoming more common as the population ages, yet osteoporosis is still underdiagnosed 1–5 . In Europe it is estimated that 1.4 million women and men aged 50–79 years will develop a new vertebral fracture each year 6 .…”

Section: Bone‐forming Agents As a New Approachmentioning

confidence: 99%

TERIPARATIDE (rhPTH 1–34) FOR THE TREATMENT OF OSTEOPOROSIS

Ebeling

Russell

2003

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYOsteoporosis is a skeletal disorder characterised by compromised bone strength predisposing a person to an increased risk of fracture. Osteoporosis develops through an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts resulting in increased bone loss. Numerous agents used for the prevention and treatment of osteoporosis slow bone loss by decreasing both bone resorption and formation. These include bisphosphonates, hormone replacement therapy, selective oestrogen receptor modulators and calcitonins. All reduce vertebral fracture risk and some reduce non‐vertebral fracture risk, but none routinely increases bone mass and strength or restores lost bone architecture. In many respects, antiresorptive therapies halt the progression of osteoporosis. However, for patients who have osteoporosis, particularly those who have sustained their first fracture and are at high risk for subsequent fractures, there is a need to develop agents that stimulate bone formation and, thus, reverse osteoporosis. Teriparatide is the recombinant human 1–34 amino acid sequence of parathyroid hormone recently approved in the US for the treatment of men and postmenopausal women at high risk for osteoporotic fracture and in Europe for the treatment of postmenopausal women with osteoporosis. When given by once‐daily injection, teriparatide increases bone mass by stimulating formation of new bone, resulting in the restoration of bone architecture.

show abstract

Osteoporosis—the disease of the 21st century?

Cited by 11 publications

References 0 publications

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis

Evaluation of current practice: compliance with osteoporosis clinical guidelines in an outpatient fracture clinic

TERIPARATIDE (rhPTH 1–34) FOR THE TREATMENT OF OSTEOPOROSIS

Contact Info

Product

Resources

About